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Abstract 
Inflammatory changes are responsible for maintenance of the atherosclerotic process and may 
underlie some of the most feared vascular complications. Among the multiple mechanisms of 
inflammation, the arterial deposition of lipids and particularly of cholesterol crystals is the one 
responsible for activation of inflammasome NLRP3, followed by the rise of circulating markers, 
mainly C-reactive protein (CRP). Elevation of lipoproteins, LDL but also VLDL and remnants, 
associates with increased inflammatory changes and coronary risk. Lipid lowering medications 
can reduce cholesterolemia and CRP: patients with elevations of both are at greatest 
cardiovascular (CV) risk and receive maximum benefit from therapy. Evaluation of the major 
drug series indicates that statins exert the largest LDL and CRP reduction, accompanied by 
reduced CV events. Other drugs, mainly active on the triglyceride/HDL axis, e.g. PPAR agonists, 
may improve CRP and the lipid pattern, especially in patients with metabolic syndrome. The 
newest most potent medications, i.e. PCSK9 antagonists, do not induce significant changes in 
inflammatory markers, but patients with the highest baseline CRP levels show the best CV risk 
reduction. Parallel evaluation of lipids and inflammatory changes clearly indicates a significant 
link, both guiding to patients at highest risk, and to the best pharmacological approach. 
 
Keywords: ezetimibe, CRP, Fibrates, LDL-C, PCSK9, statin  
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 Key messages:  
1. Lipid lowering agents with “pleiotropic” effects provide a more effective approach to CV 
prevention 
2. In CANTOS study, patients achieving on-treatment hsCRP concentrations  2 mg/L had a 
higher benefit in terms of reduction in major CV events 
3. The anti-inflammatory activity of PCSK9 antagonists appears to be of a minimal extent 
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 1. Introduction 
Inflammation has long been associated with the initiation and progression of atherosclerosis 
(1). Detection of elevated high sensitivity C-reactive protein (hsCRP) in sera of statin treated 
post-myocardial infarction patients with “residual inflammatory risk” (2), opened up a new 
front in the evaluation and treatment of patients with a high risk of recurrent events (3). The 
initial observations in patients with relatively normal lipoprotein levels and positively 
responding to statins, in the presence of isolated hsCRP elevations, gave the first 
demonstration of the validity of this approach in a number of clinical studies (4). Insights into 
the role of inflammation in the pathogenesis of atherosclerosis came also from a meta-analysis 
of 54 long-term prospective studies, comprehensive of 160,309 people without a history of 
vascular disease, reporting a continuous association of hsCRP levels with the risk of coronary 
heart disease, ischemic stroke and vascular mortality. The ability of hsCRP to predict risk is as 
large as that of cholesterol and blood pressure (5). When evaluating 23 studies in a meta-
analysis on 57 patient groups treated with different hypocholesterolemic agents (statins and 
non-statins) Kinlay reported a strong correlation between LDL-C reduction and lowering of 
hsCRP, confirming the concept of LDL-C lowering as a determinant  for the reduction in 
inflammation, possibly contributing to lower CV risk (6) (Figure 1). 
The present review article is aimed at evaluating the present-day status of the clinical 
approach to patients with an elevated CV risk. This initial evaluation will allow to better define a 
therapeutic approach. It has, in fact, been clearly reported in recent years that even after 
optimal treatment of patients with manifest vascular disease, the rate of recurrent events can 
be relatively high. These data suggest that even when all target values have been reached, 
many such patients will maintain a > 20% or even > 30% CV risk over 10 years and thus an area 
of substantial medical need is clearly present (7). 
 
2. Lipoproteins and CV risk 
In the development of vascular atheroma, in the presence or absence of inflammatory changes, 
lipoproteins still play a major role. 
 
2.1 Low-density lipoproteins. 
Low-density lipoproteins (LDL) represent the most significant accompanying biochemical 
variable associated with atheroma. The association between lowering of LDL-C and 
cardiovascular risk reduction was evaluated by Silverman across different statin and non-statin 
Ac
ce
pte
d M
an
us
cri
pt
 therapies. The relative risk of major vascular events was similar for all drug classes (statins, bile 
acid sequestrants, ezetimibe, and fibrates), and the lower achieved LDL C levels (not percentage 
reductions) were associated with a reduced incidence of major CV events (8). As recently 
reported in a meta-analysis and meta-regression analysis of 34 primary and secondary 
prevention trials of intensive (136,299 patients) vs less intensive (133,989 patients) LDL 
lowering therapy (statins, ezetimibe and PCSK9 inhibitors) clear differences were detected in 
patients who benefitted most from LDL lowering. In terms of risk reduction of total and CV 
mortality, myocardial infarction (MI), revascularization, and major adverse cardiac events 
(MACE), patients with baseline LDL-C  100mg/dL and receiving the more intensive treatment 
had the greatest benefit (9, 10). 
A number of studies indicate that elevations of LDL-C are associated with the presence 
of vascular atheromas, both as witnessed by increased vascular events as well as by the 
reduction of events in the presence of cholesterol lowering medications (11). In these 
conditions the presence of a vascular inflammatory pattern can be explained by a number of 
mechanisms, the most significant being a local inflammatory stimulus exerted by the 
cholesterol crystals, potentially a trigger of the perforation of the fibrous cap (12). Cholesterol 
crystal formation is due to an imbalance between esterified and free cholesterol as well as by 
changes in HDL function (13), involved in the reverse cholesterol transport process (14). 
Monocytes and macrophages avidly phagocytose cholesterol crystals increasing secretion of IL-
1  through activation of the inflammasome NLRP3 (15). The NOD-like receptor pyrine domain-
containing protein 3, i.e. NLRP3, in phagocytes, leads in fact to phagolysosomal damage (16). 
Reduction of cholesterolemia, e.g. by drugs, will lead to reduced cholesterol crystal formation 
and, as a consequence, to reduced atheromas. Whether reduction of the inflammatory 
potential of macrophages may occur in the absence of NLRP3 activation remains an important 
question (13). It may indicate an additional pathway to that of cholesterol reduction, since 
other lipids and lipoproteins may also a carry significant risk of both atheromas and 
inflammatory changes. 
Elevated LDL thus carry a pleiotropic risk, being associated to increased generalized 
inflammation and, because of a stimulated cellular immunity, essentially on T cells during all 
stages of disease, exerting a major role in the initiation, progression and rupture of plaques. In 
the T-cell population of human plaques, CD4+ dominate over CD8+ cells with CD4+ clones 
responding to components of oxidized LDL (17); proinflammatory T helper (Th)-1 lymphocytes 
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 aggravate atherogenesis with Th2 and Th17 further influencing lesion composition; conversely, 
regulatory T cells mitigate this process (18). 
In addition to effects elicited through inflammatory mediators, very recently a reduced 
expression of the epigenetic modifier enzyme ten-eleven translocation 2 (TET2), promoting 
expansion of clonal hematopoiesis, has been found to raise the atherosclerotic risk (19). TET2 
mutant cells leading to TET2 deficiency, when clonally expanded in the bone marrow, markedly 
increase the atherosclerotic plaque size; TET2 deficient macrophages, in addition, increase the 
NLRP-3 inflammasome mediated IL-1ß secretion. This model has allowed to note that the 
NLRP3 inhibitor, MC950, can suppress IL-1ß secretion in hyperlipidemic animal models, thus 
supporting a major role of TET2 deficiency (20). 
LDL-associated inflammatory changes have thus at least a three-pronged determination: 
1) increased LDL associates with extensive tissue inflammatory changes, mainly linked to 
increased hsCRP; 2) The rise of different T lymphocyte subtypes may lead to plaque 
proliferation and potentially rupture; 3) cholesterol crystal deposition, leading to a rise of the 
vascular inflammasome NLRP3, that may accelerate atherosclerosis development particularly in 
the presence of mutations of the epigenetic modifier enzyme TET2 (19, 20). 
 
2.1 Elevation of triglycerides (TG) in very low-density lipoproteins (VLDL)  
The inflammatory potential of VLDL is best detected in the postprandial state. Evaluation of 
postprandial (PP) TG-rich lipoproteins from normal to a hypertriglyceridemic condition has 
indicated a raised inflammatory response, particularly when PP-VLDL are combined with low 
dose TNF- as in the frequent case of elevated waist circumference (21). From these basic 
observations, clearly indicative of the inflammatory potential activity of VLDL and particularly 
PP-VLDL, the general agreement has been reached that the VLDL particles occurring in PP 
condition, so-called “remnant VLDL” (i.e. particles not completely catabolized by the lipoprotein 
lipase enzyme) can be responsible for both low-grade inflammation and for ischemic heart 
disease (22). These authors, in particular, reported the association of 38.7 mg/dL higher levels 
of non-fasting remnant cholesterol with 37% higher hsCRP levels. By a logistic regression 
analysis of their population studies (Copenhagen General Population Study and Copenhagen 
City Heart Study) a 38.7 mg/dl elevation of non-fasting remnant cholesterol was associated 
with a causal risk ratio for ischemic heart disease of 3.3 (95% CI, 2.1-5.2) vs 1.8 (95% CI, 2.1-5.2) 
for elevated LDL-C. 
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 It should be also reported that elevated plasma TG levels are identified as independent 
predictors of CVD risk even in patients who have achieved LDL-C treatment goals with statin 
therapy (23). While elevated TGs do not exert an inflammatory stimulus per se, endothelial 
damage may occur, also because of the occurrence of intravascular TGs hydrolysis via the 
activity of lipoprotein lipase either at the endothelial surface or within the arterial intima. This 
process leads to a release of free fatty acids and monoacylglycerols which generate local 
inflammation (24). A meta-regression analysis of the effects of TG-lowering in fibrate trials 
showed that a 9 mg/dL decrease in TGs reduced coronary events by 5% , the largest risk 
reduction occurring in those with baseline TGs of at least 177 mg/dL (25). In these, a 89 mg/dL 
drop in TGs associates with a -54% reduction in coronary events (7). 
 
2.2 Elevation of lipoprotein(a) 
This lipoprotein is still a disputed cause of myocardial infarction, atherosclerotic coronary and 
aortic valve stenoses (26). Elevated Lp(a) levels may not be necessarily associated with the 
development of disease, whereas a number of additional genetic variables, i.e. in particular 
small sized Lp(a), are best associated with the clinical consequences of Lp(a) elevations, in 
particular aortic valve calcification (27). The presence in Lp(a) of a cholesterol-rich LDL particle 
covalently bound to an apo (a) glycoprotein (28), allows, in fact, the transfer of associated 
cholesterol to the aortic valves, and, in addition, to other vascular atheromatous changes (29). 
Concentrations of Lp(a) are influenced by the apo(a) kringle IV2 repeat isoforms (30). 
Very recently a genome wide association metaanalysis adjusted for Lp(a) concentrations and 
apo (a) isoforms, reported a SNP increasing allele (rs186696265) both raising Lp(a) and 
increasing CAD risk (odds ratio 1.73). The apo E2 allele was also found to be a strong 
determinant of Lp(a) concentrations: each apo E2 allele can decrease Lp(a) by 3.34 mg/dL (31). 
Most interestingly, by performing a gene-based test-association study, a significant association 
of the TLR2 gene with Lp(a) was detected. Interestingly, all these genes both associate with 
raised CV risk and with tissue changes linked to inflammation. In mice, in fact, TLR2 activation 
was shown to result in a 14-fold increase in PCSK9 expression (32). 
These findings gained particular significance after the recent observation that the 
frequent splice variant G4925A associates with the smaller LP(a) isoforms, generally leading to 
enhanced cardiovascular risk (33). Surprisingly this variant does not lead to increased but rather 
to reduced CV risk from 1.39 (95% CI 1.17 and 1.66 for wild type LMW individuals) to 1.19 for 
carriers of this variant. This further observation of anomalous genetic influences on Lp(a) and 
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 CV risk need as yet to be clarified by possible links with inflammatory changes due to 
competition between Lp(a) and plasminogen, thereby antagonizing the role of plasmin in 
dissolving fibrin clots and the associated inflammatory changes (34). 
Elevated Lp(a) finally associates with oxidized phospholipids (OxPL) on apolipoprotein B-
100 (OxPL-apo B) (35). The highest tertiles of both Lp(a) and OxPL-apoB are independent 
predictors of more rapid aortic stenosis progression and also of generalized arterial disease 
(36). 
 
2.3 High density lipoproteins 
On the opposite side of these rated as atherogenic lipoproteins are high density lipoproteins 
(HDL). These are definitely associated with both a reduction in CV risk and lesser inflammatory 
changes. Calabresi et al. first outlined the mechanism whereby HDL may reduce arterial 
contractility and activation of platelet binding sites, improving endothelial function. Raised 
endothelial signaling molecules, in addition, can activate guanylate cyclase in vascular smooth 
muscle cells (37). Endothelial dysfunction is a consequence of an endothelial damage: injured 
vascular endothelial cells induce the expression of cell adhesion molecules (CAMs) by 
downregulation of TNF-α-induced CAM expression and reduced IL-6 production (38). 
In animal models of atherosclerosis, overexpression of apoAI in apoE-deficient mice 
significantly reduces CAM expression on vascular endothelial and the consequent monocyte 
recruitment into be arterial wall (39). These vascular effects of HDL are of course associated to 
their direct effect on cholesterol removal from tissues, still rated as the most valid mechanistic 
approach to vascular disease reduction (40). Very recently, changes in coronary plaque lipid 
burden, as assessed by near infrared spectroscopy, were found to be associated with even a 
modest elevation in HDL-C levels in man (41), thus underlining the role of these lipoproteins in 
reducing atheroma formation. A final mediator of HDL function is symmetric dimethylarginine 
(SDMA), a still not completely understood mediator of nitric oxide (NO) synthesis. Very recently 
(42) Zewinger et al reported that the association of SDMA with HDL leads to higher mortality, 
because of a reduction of the anti-inflammatory and regenerative properties of HDL. 
 
3. Inflammatory markers; CV risk associated to inflammatory markers and their correction 
(CANTOS Study)  
Recently, perplexities have been raised on the actual biomarker role of CRP, after a study on 
genetic loci associated with hsCRP levels failed to detect a clear link between these and the the 
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 occurrence of CV events, in contrast to neighboring loci such as IL-6R or the APOCI-CII gene 
cluster (43). A later Mendelian randomization study (44) from a coronary heart disease genetic 
collaboration, investigated individuals from 47 epidemiological studies in 15 countries and 
detected four genes tagging single nucleotide polymorphisms in the CRP gene. Variants of 
these genes were associated to an up to 30% per allele difference in hsCRP concentrations but 
were unrelated to other coronary risk factors. None of these alleles appeared to be additive to 
the classical risk scores for coronary heart disease. 
In spite of the altogether not informative genetic characterization, the results of the 
very recent CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial have 
undoubtedly shed light on the role of inflammation in atherosclerosis development. 
Canakinumab is a human monoclonal antibody against interleukin-1, approved for clinical use 
after a 48-week randomized placebo-controlled trial involving 35 patients with cryopyrin-
associated periodic syndrome (CAPS), a spectrum of autoimmune inflammatory syndromes. 
Subcutaneous administration of 150 mg canakinumab at two-monthly intervals led to a rapid 
remission of symptoms in most patients; CRP levels dropped from a baseline of 20 mg/L to 2.1 
mg/L at the end of the study (45). 
Canakinumab was generated by using transgenic mice, immunized with a recombinant 
form of human IL-1β, producing multiple high-affinity human IgG1/κ isotype mAbs (46). The 
relative molecular mass of canakinumab, based on the amino acid composition without post-
translational glycosylation, but including N-terminal pyroglutamate formation and the C-
terminal lysine residues at the heavy chains, is 145.16 kDa (47). Canakinumab binds to human 
IL-1β with high affinity and a dissociation equilibrium constant of approximately 35–40 pM (48). 
It is eliminated by intracellular catabolism following a fluid-phase or receptor-mediated 
endocytosis (49). Interestingly, although the epitope appears to be outside the IL-1β/IL-
1receptor interface, the IL-1β complexed with canakinumab does not attach to the cell surface 
receptor, thus avoiding the IL-1β-dependent signaling. 
In healthy volunteers, canakinumab shows a volume of distribution (Vd) of 5.4 L and a 
terminal half-life of 33 days. Administration of 1, 3 and 10 mg/kg canakinumab leads to a Cmax 
of 1.2, 1.2 and 1.5 pM, respectively, 42 to 56 days after the first infusion. In CAPS patients, with 
70 kg mean body weight, administration of 150 mg canakinumab led to a Cmax of 16 ± 3.5 μg/mL 
with a half-life of 26 days and Vd of 6.1 L (47, 48). In patients with systematic juvenile idiopathic 
arthritis (another therapeutic indication) clearance and Vd were 0.106 L/day and 3.2 L, 
respectively, for a body weight of 33 Kg, with an estimated half-life of 22 days (50). 
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 Interleukin-1β is a major cytokine promoting inflammation in atherosclerosis. IL-1β 
belongs to a family of 11 cytokines mediating expression of numerous genes involved in the 
immune response during infection and inflammation. Pro-IL-1β undergoes proteolytic cleavage 
to produce mature IL-1β possessing biological activity. The activation of IL-1β begets many 
molecules of IL-6 leading to the overexpression of atherothrombosis mediators (51). 
The CANTOS trial, representing a proof-of-concept for the residual inflammatory risk 
hypothesis, enrolled 10,061 patients with a previous myocardial infarction and hsCRP  2 mg/l. 
Patients were randomly assigned to receive, once every 3 months, canakinumab s.c. at the 
doses of 50 mg, 150 mg and 300 mg. Being  90% of the studied population on statins, LDL-C 
levels were around 80 mg/dl; 80% had previously undergone coronary revascularization (52). 
After a median follow-up of 3.7 years, only the dose of 150 mg led to a significant reduction of 
the primary endpoint, i.e. a composite of nonfatal MI, any nonfatal stroke, or CV death (52). 
The hazard ratio (HR) for the primary endpoint was 0.85, 95%CI: 0.74-0.98, p=0.021, with a 
number-needed to treat (NNT)) of 156 during 1 year to prevent an event. Most of the 
antiatherothrombotic effects are ascribable to the  reduction of MI in 1 year (HR: 0.76) with a 
NNT of 189 (53); CV deaths were not significantly reduced (HR: 0.88). Addition of urgent 
revascularization for unstable angina to the components of the primary endpoint led to a more 
robust statistical significance, namely a -17% decrement (HR: 0.83; 95%CI: 0.73-0.95) in major 
adverse cardiac events (MACE), i.e. -24% MIs (HR: 0.76; 95%CI: 0.62-0.92) and -37% urgent 
revascularizations (HR: 0.64; 95%CI: 0.44-0.94) (52). These findings may be consequent to a 
disproportionate benefit in patients experiencing partially occlusive events, i.e. non-ST-
segment-elevation MI and unstable angina (54). Hence, a better understanding of the clinical 
features of MIs (infarct size, Q-wave vs. non–Q-wave and spontaneous or procedure-related) 
will help to assess the definite clinical benefit of canakinumab (55). By the end of the CANTOS 
Study, canakinumab reduced hsCRP by 35% without affecting, at any dose, LDL-C (Figure 1), 
HDL-C and TG levels (56) (Table 1). No reduction in the incidence of new-onset diabetes (HR 
1.02, 95% CI 0.87–1.19) was found with a similar effect of canakinumab in reducing MACE rates 
in patients with or without diabetes (57, 58). 
Interestingly, a secondary analysis showed that, among patients allocated to 
canakinumab, those achieving on-treatment hsCRP concentrations  2 mg/L had a higher 
benefit in terms of reduction in major CV events (HR: 0.75; 95% CI: 0.66-0.85, p< 0.001), 
cardiovascular mortality (HR: 0.69; 95% CI: 0.56-0.85, p= 0.0004) and all-cause mortality (HR: 
0.69; 95% CI: 0.58-0.81, p< 0.001; Figure 2). Relative to the key prespecified secondary 
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 endpoints (non-fatal MI, non-fatal stroke, hospitalization for unstable angina requiring 
unplanned revascularization, or cardiovascular death), a 26% risk reduction was observed 
among participants treated with any dose of canakinumab who achieved hsCRP levels < 2mg/L, 
(HR: 0.74; 95%CI: 0.65-0.83; P< 0.0001) (56, 59). The benefit in reaching this hsCRP threshold is 
translated into a 5-year NNT estimate for MI, stroke, coronary revascularization, or death from 
any cause of 16. Conversely, for those participants who did not achieve on-treatment hsCRP < 
2mg/dL the 5 year NNT estimate was 57 (56, 59). 
Relative to safety concerns, although no increments in all-cause mortality and new-
onset diabetes were found (52, 57), when data from the three doses of canakinumab were 
pooled, the number of deaths from infection was significantly higher in patients on 
canakinumab vs placebo (55). 
 
4. Effects of Lipid Lowering agents on Inflammation 
4.1. Statins 
The 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (statins), can achieve a large 
reduction of plasma cholesterol and coronary artery disease (CAD). Statins inhibit the 
biosynthesis of cellular cholesterol in the liver, thus resulting in an increased expression of the 
LDL receptor and uptake of LDL cholesterol from the circulation. A meta-analysis from the 
Cholesterol Treatment Trialists’ (CTT) Collaboration from 90,000 individuals in 14 randomized 
trials of statin therapy, demonstrated a weighted mean difference of about 1.0 mmol/L in LDL 
cholesterol and a proportional reduction of (about 20%) of major vascular events (defined as 
coronary death, non-fatal myocardial infarction, coronary revascularization, or stroke) (60). 
At the pharmacokinetic level (i.e., absorption, distribution, metabolism, and excretion of 
a given drug) available statins display important differences, including half-life, systemic 
exposure, maximum plasma concentration (Cmax), bioavailability, protein binding, lipophilicity, 
metabolism, presence of active metabolites, and excretion routes (61). 
It is usually assumed that any beneficial effect of statins on coronary events is linked to 
their hypocholesterolemic properties. However, because mevalonic acid, intracellularly 
synthesized by HMG-CoA reductase, is the precursor of numerous metabolites, inhibition of 
HMG-CoA reductase has the potential to result in pleiotropic effects (62, 63); hence, effects 
other than cholesterol reduction may help  explain the anti-atherosclerotic properties of 
statins, such as improvement of endothelial function and reduction of platelet aggregation, 
increased number and activity of endothelial progenitor cells, inhibition of migration and 
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 proliferation of smooth muscle cells, stabilization of coronary plaques and atheroma regression 
(64-66). 
Among all these pleiotropic effects, statins were shown to reduce CRP levels, and for 
this reason to exhibit anti-inflammatory properties. However, statins, by reducing LDL-C levels, 
decrease the number of LDL particles, that can infiltrate vessel walls, thus limiting 
atherosclerosis progression and local inflammation. The reduction of CRP could be thus related 
to the lipid lowering effect of statins. The mutual relationship between inflammation and lipid 
metabolism is also dictated by the fact that pro-inflammatory cytokines regulate the 
transcription of many genes involved in cholesterol and TG synthesis (67, 68). 
The first study showing a lowering effect of statins on hsCRP was the CARE (Cholesterol 
and Recurrent Events) trial. This study showed that the relative CV risk reduction attributable to 
statin treatment was larger in patients with elevated hsCRP (69). This observation was 
subsequently confirmed in other studies, such as the Air Force/Texas Coronary Atherosclerosis 
Prevention Study (AFCAPS/TexCAPS), REVERSAL (Reversal of Atherosclerosis with Aggressive 
Lipid Lowering), PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection 
Therapy–Thrombolysis in Myocardial Infarction 22) and A to Z (Aggrastat-to-Zocor) (2, 70-72) 
(Table 1). All these led to hypothesize a dual goal for an antiatherosclerotic therapy, the largest 
clinical benefit being found in patients not only achieving LDL-C below 70 mg/dL but also hsCRP 
below 2 mg/L (73). This concept was then confirmed in the primary prevention JUPITER trial on 
18,000 patients with median LDL-C of 108 mg/dL and elevated hsCRP (>2.0 mg/L) (74). 
Rosuvastatin 20 mg reduced by half the rate of major CV events such as stroke, nonfatal 
myocardial infarction, revascularization, unstable angina or death from CV causes (74), thus 
supporting the conclusion that on-treatment levels of hsCRP are as important for predicting 
recurrent disease as on treatment levels of LDL-C. Furthermore, the largest reduction in CV 
events (-65%), occurred in patients achieving both LDL-C < 70 mg/dL and hsCRP < 2 mg/dL 
compared to those achieving only one of the two targets (-33%) (75). 
In the MIRACL (The Myocardial Ischemia Reduction with Acute Cholesterol Lowering) 
and REVERSAL trials, the effect of statins on CRP was shown to be dose dependent, with a 
higher reduction after more aggressive therapy (atorvastatin) compared to standard therapy 
(pravastatin) (6, 76) (Table 1). 
In addition to the effects of statins on hsCRP and systemic inflammation, some clinical 
evidence has suggested that statins can ameliorate the vascular inflammatory status, in 
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 particular improving endothelial function in patients with cardiovascular risk or CAD (77, 78), 
with a well-defined timing and potency related effect (79). 
While there is no doubt that statins can improve systemic inflammation (reduction of 
hsCRP), whether this action is related to their lipid lowering properties is still a matter of 
discussion (43, 44, 80). The effects of statins on hsCRP are likely to be related to a general 
positive effect on other atherogenic players that determine the final anti-inflammatory action, 
and statins may elicit their pleiotropic effects independent of their lipid lowering activity. Thus, 
the reduction of LDL-C levels with a mechanism not involving HMG-CoA reductase, could 
certainly help to better define the relationship between hsCRP and LDL-C and to potentially 
clarify the direct benefit of hsCRP reduction on cardiovascular disease. 
Statins thus display significant anti-inflammatory effects, also leading to some non-lipid 
indications, e.g. for the treatment of periodontal inflammation (81), where periodontal 
responses were associated with changes in carotid inflammation. Reduction of hsCRP appears 
to be related to LDL-C lowering and may be an important determinant of CV risk reduction 
(Figure 1). 
 
4.2 Ezetimibe 
Ezetimibe is an inhibitor of the cholesterol transport protein NPC1-like 1 and reduces intestinal 
cholesterol absorption (82). When added to statin therapy, ezetimibe resulted in incremental 
lowering of LDL-C levels and improved cardiovascular outcomes (2% reduction of absolute risk) 
(83). 
Following oral administration, ezetimibe is rapidly glucuronidated in the intestines and 
the glucuronide undergoes enterohepatic recirculation which explains the long duration of 
action accounting for a half-life of 22h (84). Ezetimibe does not interact with drugs metabolized 
by CYP450 1A2, 2D6, 2C8, 2C9, or 3A4, and, in particular, does not interact with statins. 
In an experimental study on rabbits on a high fat diet and femoral atherosclerosis, 
ezetimibe treatment was associated with both reduced atheroma progressions and plaque 
stabilization: CRP levels were significantly reduced with no further reduction by the addition of 
simvastatin (85). Somewhat divergent data have been provided by the clinical studies: the 
majority of these have been, in fact, conducted in combination with statins and a small number 
as monotherapy. A pooled analysis of randomized, placebo-controlled trials of ezetimibe 10 
mg/day in patients with hypercholesterolemia, showed no significant difference on hsCRP 
levels (+5% and -1% for placebo and ezetimibe group, respectively). On the contrary, when 
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 ezetimibe was added to baseline statin therapy a -10% reduction of hsCRP was observed (-1% 
vs -12% for placebo plus statin and ezetimibe plus statin, respectively) (86). A very similar effect 
was observed in the IMPROVE-IT trial, where the addition of ezetimibe to simvastatin therapy 
resulted in a further -20% reduction of LDL-C and a -14% (0.3 mg/L) reduction of hsCRP (87). 
This translated into significantly more patients meeting both of the prespecified targets of LDL-
C<70 mg/dL and hsCRP<2 mg/L in the ezetimibe/simvastatin group compared to simvastatin 
alone (-50% vs -29%) (87). Again, in the SHARP trial, that recruited patients with chronic kidney 
disease, the combination simvastatin/ezetimibe produced a -35% reduction of LDL-C vs placebo 
and a -21% reduction of hsCRP (88) (Table 1). 
A number of studies have investigated statin therapy versus statins in combination with 
ezetimibe on endothelial function as a measure of vascular inflammation (77, 89-96). Results 
were found to be inconstant: six studies found no difference in endothelial function (89, 91, 94, 
96-98), four  found statin alone be better (77, 92-94), and one study found a beneficial effect of 
combination therapy over statin alone (90). However, in many of these studies comparing 
statins vs combination therapy, markedly different lipid lowering effects were found, thus 
making comparisons difficult (77, 89-91, 94). Two cross-over studies with a reduced risk of 
confounding and bias, reached discordant conclusions, one showing an improved endothelial 
function on statin alone (93), and the other not observing any significant difference between 
the two treatments (97). 
Ezetimibe can thus provide an additive effect to that of statins both on LDL-C and on 
hsCRP-lowering (Figure 1). The mechanism of this latter effect is not fully clarified. 
 
4.3. Fibrates 
Fibrates are activators of the peroxisome proliferator-activated receptor (PPAR) system, mainly 
PPAR-α, and have shown a significant benefit in clinical trials of CV prevention, i.e. reducing the 
occurrence of nonfatal MI, particularly when restricting evaluation to patients with 
concomitant TG elevation and HDL-C reduction (99, 100). In this context, results from the long-
term (10 years) extension of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) 
trial confirmed the significant preventive benefit of fenofibrate in patients with combined 
elevation of TG and reduction of HDL-C levels (101). 
Fenofibrate is rapidly hydrolysed after absorption, to fenofibric acid, the major active 
metabolite. The drug is excreted unchanged in urines either as fenofibric acid or as its 
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 glucuronide conjugate. No hepatic microsomal metabolism is involved, not being fenofibric acid 
a substrate for CYP3A4 (102). 
A recent meta-analysis evaluated hsCRP changes after fibrates and reported that these 
are correlated with HDL-C rises, in particular a mean 1% elevation in HDL corresponding to a -
2.03% decrement in hsCRP (103).  Administration of fibrates led to a significant overall mean 
hsCRP reduction of -0.47 mg/L (95% CI: -0.93, -0.01), mainly ascribable to trials recruiting 
patients with baseline CRP  3 mg/L (-1.01 mg/L; 95% CI: -1.86, -0.16). The effect was lost when 
baseline hsCRP values were  3 mg/L (-0.25 mg/dL; 95% CI: -0.74, 0.25; p=0.33). These findings 
were not fully confirmed by a sub-analysis of the FIELD (Fenofibrate Intervention and Event 
Lowering in Diabetes) trial, originally designed to assess the effect of fenofibrate on CV events 
in patients with type 2 diabetes (T2D) (104). In FIELD a 5-year treatment with fenofibrate 
significantly reduced LDL-C (14.2%) but not hsCRP (+ 0.8 mg/L). These findings did not differ 
when patients were stratified for the hsCRP cut-off of 2.0 mg/L (105) (Table 1). 
 In an attempt to reduce the residual CV risk in high-risk patients with mixed 
hyperlipidemia, e.g. in T2D, the addition of a fibrate to statin therapy has been suggested (106). 
However, although a fibrate–statin combination may reduce to a greater extent total 
cholesterol (−2.2%; 95% CI: 1.9–2.5), LDL-C (−2.3%; 95% CI: 2.0–2.5), and TGs (−0.4%; 95% CI: 
0.2–0.6) compared to statin alone, a higher risk of side effects (muscular and consequently 
renal) may occur with gemfibrozil, to a lesser extent with fenofibrate and bezafibrate (61, 107). 
The DIACOR (Diabetes and Combined Lipid Therapy Regimen) trial directly evaluated a 
12-week treatment with fenofibrate, simvastatin or their combination (fenofibrate 160 mg and 
simvastatin 20 mg) in T2D patients with mixed dyslipidemia and no history of CV events. hsCRP 
levels were reduced by -18.9%, -24.9% and -27.3%, respectively, but the combination therapy 
was not more effective than either fenofibrate or simvastatin alone (108) (Table 1). Similarly, 
no additional benefit of a combination therapy on hsCRP reduction was seen in patients with 
mixed dyslipidemia receiving rosuvastatin (40 mg), as monotherapy, or as an add-on therapy to 
fenofibrate (200 mg). Rosuvastatin monotherapy led to a 56% reduction in hsCRP vs baseline, 
whereas the combination with fenofibrate, unexpectedly, did not change hsCRP levels (109). 
Confirming prior studies, instead, in patients with mixed dyslipidemia, rosuvastatin (40 mg), 
rosuvastatin (10 mg) plus fenofibrate (200 mg) or rosuvastatin (10 mg) plus omega 3 (2 g) 
resulted in a -53%, -28% and -23% reductions in hsCRP, respectively, vs baseline (110). 
In the attempt to improve the lipid profile in patients in patients with mixed 
hyperlipidemia, characterized by both hypercholesterolemia and hypertriglyceridemia, fibrate 
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 co-administered with ezetimibe has been proposed. In a 48-week trial, enrolling 576 patients 
with LDL-C 130 to 220 mg/dL and TGs 200 to 500 mg/dL, the co-administration of fibrate plus 
ezetimibe was more effective than fenofibrate alone in reducing LDL-C (-22% vs -8.7%), TGs (-46 
% vs -41.8%) and non-HDL-C (-31.6% vs -19.4%). Both treatments significantly reduced hsCRP vs 
baseline, with no further benefit of adding ezetimibe to fenofibrate (-25.3% vs -21.1%) (111) 
(Table 1). 
Fibrates thus improve inflammatory changes in conditions of hyperlipidemia. Reduction 
of the major marker, hsCRP, appears to be related to the rise of HDL-C (98) and may be additive 
to the effects of statins and ezetimibe. No definitive data are available on the possible influence 
of this pleiotropic activity on the reduction of CV risk. 
 
4.4. Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists 
Proprotein convertase subtilisin/kexin 9 (PCSK9) is a liver-secreted plasma protein that, by a 
post-translational mechanism, regulates the number of cell-surface LDL receptors (LDL-R), thus 
inhibiting LDL uptake. Indeed, by binding to the epidermal growth factor–like repeat homology 
domain A of human LDL-R, PCSK9 has a dual effect (i) acting as a courier, facilitating the exit of 
LDL-R from the endoplasmic reticulum, and (ii) fostering the degradation of the LDL-R at the cell 
surface (112-114). Thus, in order to increase the number of LDL-R, inhibition of PCSK9 has been 
achieved by mean of monoclonal antibodies (mAbs). Two fully human IgG1 and IgG2 mAbs, 
alirocumab and evolocumab, respectively, have been approved in the United States and in the 
European Union in August 2015, whereas bococizumab, a humanized mAbs, has been 
discontinued in November 2016 (115, 116). Interestingly, other approaches to inhibit PCSK9 are 
being developed, i.e. antisense oligonucleotides, small-molecule inhibitors, and RNA 
interference therapies (inclisiran) (117) and a vaccine (118). 
The pharmacokinetics of PCSK9 inhibitors is closely related to the biochemical 
characteristics of monoclonal antibodies. Absolute bioavailability is 72% for evolocumab and 
85% for alirocumab, with distribution volumes of 3.3 L and 3.0–3.8 L, respectively, confirming 
the limited tissue distribution of mAbs. Effective plasma half-lives are 11-17 days for 
evolocumab (119) and 17-20 days for alirocumab (120), reduced  by statin co-administration. 
Indeed, evolocumab clearance is increased by about 20%, partially due to the statin-driven 
upregulation of PCSK9. Similarly, alirocumab exposure was reduced by about 40%, 15%, and 
35% when administered with statins, ezetimibe, and fenofibrate, respectively (121). However, 
these drug-drug interactions are not to be rated as clinically meaningful and do not require 
Ac
ce
pte
d M
an
scr
ipt
 dose adjustment. Proteolytic and target-mediated elimination pathways have been described: 
the first one prevails in the presence of high drug concentrations, whereas the second becomes 
prevalent at low concentrations. 
So far, the Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) approved the use evolocumab for cholesterolemia reduction in the homozygous (HoFH) 
and heterozygous forms of familial hypercholesterolemia (HeFH)), in addition to diet and 
maximum tolerated statin doses, in order to prevent CV events (122); alirocumab is instead 
indicated only for the treatment of HeFH (120). 
In addition to the most characterizing feature of mAbs activity, i.e. LDL-cholesterol 
lowering (up to 50-60%) in very high-risk patients (123, 124), especially FH (125), data from 35 
RCTs (45,539 subjects) have shown that administration of  these two mAbs is associated with a 
lower rate of MIs (Odds Ratio (OR): 0.72; 95% CI: 0.64-0.81), strokes (OR: 0.80; 95% CI: 0.67-
0.96) and coronary revascularizations (OR: 0.78; 95% CI: 0.71-0.86) not of mortality (126). These 
findings have been confirmed in a subsequent meta-analysis from 11 RCTs including 38,235 
participants, treated with evolocumab and alirocumab for at least 48-weeks (127). 
PCSK9 circulating levels have been related to a large number of CVD risk factors, i.e. LDL-
cholesterolemia (128), TGs (129), Lp(a) (130), atherogenic lipoproteins (131), arterial stiffness 
(132), and platelet activation (133). Moreover, a significant proportion of plasma PCSK9 (20–
40%) circulates bound to lipoproteins, i.e. LDL and Lp(a) but not HDL (134). 
The relationship between PCSK9 and the inflammatory process is the object of intensive 
investigation. While, in fact, inflammation raises PCSK9 liver expression (135) and PCSK9 is 
positively linked to TNF-α levels (136), no significant relationship has been observed between 
PCSK9 levels and hsCRP (137). This last finding is in line with the observation that PCSK9 
antagonists do not apparently exert a significant anti-inflammatory activity in treated patients, 
at least as witnessed by a lack of reduction of hsCRP (weighed mean difference - WMD: 0.002 
mg/L; 95%CI: -0.017, 0.021; p= 0.807). This conclusion is supported by the selective evaluation 
of alirocumab (WMD: 0.15 mg/L) and evolocumab (WMD: 0.002 mg/L) (138). Notably, data 
from the ODYSSEY COMBO II trial showed that alirocumab may work better in CV patients with 
residual lipid risk (LDL-C >70 mg/dL), vs those with residual inflammatory risk (CRP > 2 mg/dL) 
(139). In this study, aimed at comparing the efficacy of alirocumab vs that of ezetimibe, this 
latter reduced, although not significantly, the hsCRP levels by -25% vs no changes in patients 
given alirocumab (140). After 52 weeks of treatment, LDL-C dramatically dropped by -49.5% in 
the alirocumab arm vs -18.3% in ezetimibe patients (140) (Table 1). 
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 Interestingly, this lack of efficacy in reducing hsCRP persists independent of the 
mechanism by which PCSK9 is lowered; indeed, among patients at high risk of CV disease, 
allocated to receive a single dose of 200, 300, or 500 mg of inclisiran or a two-dose regimen of 
100, 200, or 300 mg of inclisiran, only a modest -16.7% (-50.9 to +33.3; p< 0.05) decrement in 
hsCRP levels was found in the arm (n= 59) receiving inclisiran 300 mg in the two dose regimen 
(141). 
In a head-to-head analysis of mortality differences between the FOURIER (Further 
Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and 
the CANTOS trials, Ridker hypothesized that the lack of efficacy of evolocumab on 
cardiovascular or all-cause mortality may be due to the different baseline hsCRP levels, 
exceeding 4mg/L in CANTOS, but less than 2mg/L in FOURIER. Baseline LDL-C concentrations 
were instead similar in the two RCTs, i.e. 82 mg/dL in CANTOS vs 89 mg/dL in FOURIER (142). A 
post hoc analysis of the FOURIER trial reaffirms the importance of inflammatory and residual 
cholesterol risks, being LDL-C and hsCRP, in this trial, independently associated with the 
primary outcome. When patients were stratified according to baseline hsCRP, i.e. <1, 1-3, and 
>3 mg/dL, absolute reductions were larger in patients with higher hsCRPs: 1.6%, 1.8%, and 2.6% 
and 0.8%, 2.0%, and 3.0%, respectively, for the primary and key secondary endpoints across 
hsCRP strata (143). Moreover, even among patients achieving an LDL-C <20 mg/dL, the highest 
CV risk associated with the hsCRP stratum: a 3-year primary event rate of 9.0%, 10.8% and 
13.1% occurred with hsCRPs of <1, 1 to 3 or >3 mg/L, respectively (143) (Table 1). 
These observations are in line with prior data analysis, reported by Catapano et al., 
observing how in RCTs with anti-PCSK9 therapies, median baseline hsCRPs were below 2 mg/dL. 
Indeed, when clinical trials with hsCRP levels > 2 mg/L are considered, hsCRP are reduced by 
any lipid-lowering agent, independent of the mechanism of action (144). 
Interestingly, the FOURIER trial highlighted how the severity and extent of coronary 
artery disease are leading features, in order to identify people who benefit the most from LDL-C 
lowering with evolocumab. Recent MI, multiple prior MIs, and residual multivessel coronary 
disease were independent predictors of CV outcomes, leading to an absolute risk reduction of 
over 3% in high risk vs. approximately 1% in low-risk groups, respectively. In patients with at 
least 1 high-risk feature there was a relative risk reduction in CV death, MI or stroke of 19% 
(HR: 0.81; 95%CI: 0.68-0.95) during the first year and of 27% (HR: 0.73; 95%CI: 0.62-0.86) 
beyond the first year (145). 
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 Another controversial point is whether the reduction of CV events in clinical trials with 
PCSK9 mAbs is related to a drop in LDL-C or in hsCRP: this will be better clarified once data from 
the ODISSEY OUTCOME (Evaluation of Cardiovascular Outcomes After an Acute Coronary 
Syndrome During Treatment With Alirocumab) trial will be fully available. Administration of 
alirocumab in patients with a recent acute coronary syndrome, already on intensive or 
maximum-tolerated statin therapy, reduced MACE (including all-cause mortality and MI) by -
15%, going down to -24% in patients with baseline LDL-C  100 mg/dL, deriving the largest 
benefit (146, 147). However, in the interpretation of these findings three important points 
should be  borne in mind: among patients assigned to alirocumab (i) if at one month LDL-C 
remained at ≥50 mg/dL the dose of alirocumab was titrated in a blinded fashion to 150 mg 
every 2 weeks; (ii) if on 2 consecutive evaluations LDL-C was <25 mg/dL, then the dose of 
alirocumab was reduced from 150 to 75 mg and (iii) if LDL-C was <15 mg/dL at 2 consecutive 
visits on alirocumab 75 mg, treatment was stopped (148). 
The debate on whether or not LDL-C and hsCRP are inseparable markers of risk, was 
further addressed in a post hoc analysis of SPIRE-1 and -2 (Studies of PCSK9 Inhibition and the 
Reduction of Vascular Events) trials, with bococizumab. While this latter led to a dramatic 
reduction in LDL-C (-60.5% at 14 weeks) a monotonic increase in the incidence of   the primary 
endpoint (myocardial infarction, stroke, unstable angina requiring urgent coronary 
revascularization, and cardiovascular death) was noted. When patients were stratified 
according to on-treatment hsCRP levels, i.e. <1 (Reference value), 1-3, and >3 mg/L the Hazard 
ratios were 1, 1.16 (95%CI 0.81-1.66) and 1.62 (95%CI 1.14-2.30) (149) (Table 1). 
An improvement in endothelial function after a 2-month therapy with evolocumab has 
been also described an effect proportional to the LDL-C reduction. Indeed, a -59% drop in LDL-C 
levels corresponded to a rise in flow-mediated dilation (+40%), brachial artery diameter (peak 
values 0.39  0.09 vs 0.36  0.11 cm) and velocity time integral (peak levels 96  1 vs 85  9 
cm). This evidence is in line with previous studies reporting a positive association between 
PCSK9 and endothelial function markers, e.g. blood pressure and arterial stiffness (132, 150-
152). 
The anti-inflammatory activity of PCSK9 antagonists thus appears to be of a minimal 
extent (Figure 1); it has not been evaluated after the long-acting siRNA antagonist inclisiran 
(153). This does not exclude the possibility that individual hsCRP elevations may identify 
patients getting the largest benefit from PCSK9 antagonism. 
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 PCSK9 antagonists display also a clear lowering effect on Lp(a) levels, compared to the 
absence of effect by statins. The Lp(a) reductions was roughly 25% (154) by as yet unclear 
mechanisms. It appears the reductions are achieved through two different mechanisms. When 
administered as monotherapy, evolocumab reduces the production rate of Lp(a), not of 
fractional catabolic rate (FCR) (155). Differently when given in combination with atorvastatin 
the FCR of Lp(a) increases significantly, without alterations of the production rate. This most 
recent study differs somewhat from previous findings. A prior study, with alirocumab vs 
placebo a reduction of plasma Lp(a) levels 18.7% (p < 0.001) was observed. This reduction 
appeared to be associated with a trend for an increase of median FCR of apo(a) (+24.6%, 
p=0.09) with no change in the production rate (156). 
The mechanism/s underlying these discordant findings may be possibly related to 
differences in Lp(a) baseline levels, age, body mass index and ethnicity. Apo(a) isoform size may 
play also a role, influencing both production and catabolism of Lp(a) particles (157). The Lp(a) 
lowering activity of PCSK9 antagoniss may be also related to the dramatic LDL-C reduction, thus 
reducing a possible competitor for the binding to the LDL-R, although targeted studies 
addressing this mechanism did not clearly indicate an involvement of the LDL-R in the uptake of 
Lp(a) (158). It may not be, of course, to be excluded that additional receptor/pathways may be 
involved in the clearance of Lp(a) (159). 
Most recently, inclisiran has been evaluated in terms of Lp(a) reduction. In this study, 
patients on maximal tolerated drug therapy received single (200, 300 and 500 mg) or two dose 
starting regimens (100, 200 or 300 mg on days 1 and 90) vs placebo. In addition to the expected 
reduction of LDL-C and apo B levels, changes of Lp(a) were indicative of a general trend to 
reduction, 80% of participants showing reduced Lp(a) levels at the end of the trial. However, 
due to the very large variability of levels, none of the difference reached statistical significance 
(153). 
 
4.5 Bile acid sequestrants 
Bile acid sequestrants (BAS) bind bile acids in the intestine through anion exchange, resulting in 
decreased enterohepatic recirculation of bile acids. This promotes liver conversion of 
cholesterol to bile acids. The reduction in the hepatocyte cholesterol content enhances LDL-R 
expression, that leads to lowering of   LDL-C levels. Three BAS are currently available: 
cholestyramine, colestipol and colesevelam. Only two randomized controlled trials evaluated 
the effects of BAS on CHD risk. The Lipid Research Clinics Coronary Primary Prevention Trial 
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 evaluated use of cholestyramine 24g/day versus placebo in patients  with type II 
hyperlipoproteinemia free of CHD (160). Cholestyramine determined a significant -8% LDL-C 
reduction, determining a -19% lower risk of the primary end point (CHD death and nonfatal MI) 
after 7.4 years of follow-up (160). Colestipol (5 g three times daily vs placebo) has been 
investigated for efficacy, safety, and effects on mortality in CHD patients (161). Colestipol 
significantly reduced total cholesterol (-32 mg/dL) and raised TGs (+33 mg/dL) vs placebo and 
was associated with a significant reduction in CHD deaths in men, not in women (161). 
Colesevelam hydrochloride is a newer BAS, specifically designed with a unique structure 
for the purpose of improving tolerability and reducing potential drug interactions compared to 
older BAS. Colesevelam HCl is hydrophilic, insoluble in water, and is administered orally as a 
solid tablet, containing 625 mg of the product, not hydrolyzed by digestive enzymes and not 
undergoing intestinal absorption. It is excreted exclusively in the feces. 
When given as monotherapy, six 625 mg tablets colesevelam HCl per day, reduced LDL-C 
by -15% to 21%, increased HDL-C by 3%-9%, and  TG levels by 2%-16% compared to placebo 
(162). Compared to statin alone, colesevelam HCl in combination with statins, further 
decreased LDL-C by -10% to 16%, increased HDL-C by 3%–7%, and TG levels by 5%–23% (162). 
Colesevelam HCl was the first BAS reported to reduce hsCRP when added to statins (163). The 
results derived from three clinical trials of similar design and methods, investigating the efficacy 
of adding colesevelam HCl, compared with placebo, in hypercholesterolemic patients on stable 
simvastatin, atorvastatin, or pravastatin therapy (163). Pooled analysis of the three trials 
showed that the groups receiving the BAS plus statin  had significantly larger mean reductions 
in LDL-C levels (-10.2% vs -21.0%) and  produced a further significant reduction of hsCRP (-2.0 vs 
1.3 mg/L; -23.3%) (163) (Table 1). 
Thus, the results from these trials showed that combining colesevelam HCl with either 
simvastatin, atorvastatin or pravastatin determines a significantly greater median percent 
reduction in hsCRP levels. 
A third generation BAS, colestimide (also known as colestilan, marketed only in Japan) 
was also reported to reduce hsCRP levels (164). Japanese patients with diabetes mellitus 
complicated by hyperlipidemia and metabolic syndrome were enrolled and treated with 
pitavastatin or colestimide (164). Pitavastatin and colestimide reduced LDL-C by -45.3% and -
14.4%, respectively. Pitavastatin only slightly reduced hsCRP after 24 weeks of treatment (from 
8.76 mg/L to 8.27 mg/L; -5.5%) whereas colestimide exerted a much greater reduction (from 
10.16 mg/L to 5.86 mg/L; -42.3%) (164) (Table 1). 
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  BAS, while not extensively investigated (first generation cholestyramine and colestipol 
were developed way before the inflammatory mechanism of atherosclerosis was postulated) 
appear to produce a greater anti-inflammatory activity than expected (Figure 1). While 
colesevelam significantly adds to the hsCRP reducing activity by statins, the comparative 
evaluation of colestimide with pitavstatin suggested a dramatic hsCRP lowering potential. 
 
4.6 Lomitapide and Mipomersen 
Two drugs have been developed for the treatment of extreme cholesterol elevations, i.e. 
homozygous hypercholesterolemia. One of them, mipomersen is an apolipoprotein B synthesis 
inhibitor, acting as an antisense oligonucleotide, binding to the mRNA coding for apo B100. 
Mipomersen, mainly because of the high number of side effects, related to the s.c. 
administration, has not been approved for use outside of the US.  Lomitapide is instead an 
agent affecting the microsomal triglyceride transfer protein (MTP). Inhibition of MTP prevents 
the assembly of apo B containing lipoproteins in enterocytes and liver cells. Lomitapide has 
been approved worldwide for the treatment of homozygous hypercholesterolemia. 
 
4.6.1 Lomitapide 
Lomitapide has an absolute bioavailability of approximately 7%, suggesting a significant first-
pass effect. The steady state volume of distribution is about 985–1292 L, being 99.8% plasma-
protein bound. It is extensively metabolized by CYP3A4 and co-administration with strong 
CYP3A4 inhibitors, e.g. ketoconazole or, to a more modest extent, atorvastatin, increase the 
systemic exposure of lomitapide (165). The metabolites of lomitapide are essentially devoid of 
pharmacological activity. About 52.9-59.5% of the drug are eliminated by urinary and 33.4-
35.1%   by the fecal routes; the terminal half-life is 39.7 h (166, 167). 
Lomitapide administration is mainly associated with gastrointestinal disturbances, 
generally overcome after prolonged treatment (167). Clinical studies have generally not been 
addressed to the evaluation of inflammatory/anti-inflammatory markers, but of special interest 
is the very long study on efficacy/safety in homozygous hypercholesterolemic patients (168). 
Extensive evaluation of patients over 246 weeks of treatment noted, in addition to a very 
effective LDL-cholesterol reduction (-45.5%) maintained for duration of the trial, a moderate 
rise in liver fat (from 0.7 to 10.2%) and, most interestingly, a progressive reduction of hsCRP, 
resulting in a highly significant change, i.e. -60% from baseline to week 24 (Table 1). 
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 This finding is difficult to explain but certainly of high clinical interest, since the 
occurrence of cardiovascular events has been minimal in patients treated for these very long 
periods. It differentiates lomitapide from PCSK9 antagonists, having no activity on CRP levels 
(138). It may be possibly linked to the drug’s activity on the human ether-a-go-go-related gene 
(hERG) channel currents. Inhibition has been observed only at high concentration (>1.7 µM) 
relative to those achieved at clinical dosing (166). However, a similar activity on hERG channels 
is exerted by COX2 antagonists, e.g. celecoxib (169) and is certainly linked to hsCRP reduction. 
The parallel activity of lomitapide and celecoxib on hERG channels and hsCRP may thus be 
explained by a common mechanism. Pharmacological connection of hERG channel inhibition 
and drug-induced prolongation of QT intervals has not come out of clinical studies on either 
celecoxib or lomitapide. 
 
4.6.2 Mipomersen 
Mipomersen is rapidly absorbed from the injection site into the circulation, with peak plasma 
concentrations within 3–4 h. No differences in AUCs have been reported between routes of 
administration (i.v. or s.c.). Relative to i.v. administration, the estimated absolute bioavailability 
ranges from 54% to 78%. About 85% of mipomersen is bound to plasma proteins being albumin 
the prominent one. Tissue endonucleases cleave the molecule to chain-shortened metabolites 
that no longer retain pharmacological activity. Urinary excretion represents the main route of 
whole-body clearance for both parent drug and metabolites. Following s.c. administration, the 
elimination half-life is approximately 1 to 2 months (170, 171). 
Mipomersen has been evaluated in a single study, to a limited extent, as potentially 
acting on inflammation. Flaim et al (172) tested the tolerability in healthy volunteers, 
determining plasma concentrations across three dose regimens. LDL-C reductions ranged 
between -9.5 and   -21%. There were no significant changes in pro-inflammatory or anti-
inflammatory markers, except for a rise in post-dose hsCRP in the mipomersen 200 mg weekly 
group. It appears thus as unlikely that mipomersen may display any significant anti-
inflammatory actions, also considering that the major side effects are the frequent occurrence 
of flu-like symptoms and injection site reactions (173). 
In conclusion, lomitapide and mipomersen in clinical use for extreme lipid elevations 
appear to differ in terms of possible inflammatory/anti-inflammatory mechanisms. 
Mipomersen, an antisense DNA drug, leads to local inflammation and flu-like symptoms not 
associated with hsCRP reduction, but rather rises. Dramatic reductions of hsCRP have instead 
Ac
ce
pte
d M
an
us
cri
pt
 been observed after long term lomitapide and appear to be of potentially high clinical interest 
in the CV preventive activity. 
 
4.7 Bempedoic acid 
Bempedoic acid is a novel synthetic lipid-lowering agent targeting ATP-citrate lyase. ATP-citrate 
lyase (ACL) is a seldom-evaluated enzyme target, uniquely positioned at the intersection of 
nutrient catabolism and fatty acid biosynthesis. The ACL reaction is primarily responsible for the 
production of extra-mitochondrial acetyl-CoA (174), serving as the carbon precursor for 
cholesterol and fatty acid biosynthesis, as well as a metabolic checkpoint used by cells to sense 
nutrient availability and to coordinate metabolic adaptations. Bempedoic acid provides thus an 
effective therapeutic modality to treat hypercholesterolemia and to potentially address 
metabolically linked disorders such as non-alcoholic fatty liver disease. By a Mendelian 
randomization study the effects of lowering LDL-C levels were found to be mediated by 
multiple independent single nucleotide polymorphisms (SNPs) in the region encoding the ACLY 
gene (175). 
The efficacy of bempedoic acid as an LDL-C lowering agent has been validated by the 
positive results of phase 3 studies, indicating a stable LDL-C reduction in the range of 25-35%, 
additional to that of statins, with minimal muscular side effects (176). Bempedoic acid is, in 
fact, a pro-drug activated to the-CoA derivative in the liver by the very-long-chain acyl-CoA 
synthase 1 (ACSVL1). The active derivative inhibits ACL in the liver, whereas no conversion 
occurs in skeletal muscle, lacking ACSVL 1 (177). Thus, different from statins, no significant 
amount of active drug reaches skeletal muscles, with consequent minimal risk of myalgia. 
Kinetic data on bempedoic have not, yet, been made available (Esperion Therapeutics, personal 
communication). 
Clinical studies have consistently shown a marked hsCRP lowering activity of bempedoic 
acid. The highest efficacy has been reported in diabetic patients (178), i.e. -41% with a similar 
LDL-C reduction on a daily dose of 120 mg. In hypercholesterolemic patients (LDL-C: 130-220 
mg/dl, stratified by baseline TGs), hsCRP reductions of 20÷26% not dose-related, were 
described (179). More recently, in patients intolerant to at least one statin with a history of 
muscle complaints, a median -42% hsCRP reduction was reported with daily doses up to 240 
mg; bempedoic acid reduced LDL-C 28.7% more than placebo (180). In the CLEAR Tranquility 
trial, enrolling 269 statin intolerant patients, treatment with bempedoic acid (180 mg) added to 
background lipid-modifying therapy that included ezetimibe reduced LDL-C and hsCRP by -
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 28.5% and -31%, respectively  (181) (Table 1). The long-term safety and efficacy of bempedoic 
acid as well as the CV outcomes are being evaluated in other 3 ongoing clinical trials (182). 
Finally, data from a phase 2b study, showed that in hypercholesterolemic patients (LDL-
C, 130-220 mg/dL) with or without muscle-related intolerance to ≥2 statins, combination of 
bempedoic acid (120 or 180 mg) with ezetimibe (10 m/day) dramatically reduced LDL-C 
cholesterol up to -48% with, in addition, a maximal -40.2% reduction in hsCRP when bempedoic 
was administered as a monotherapy (183). 
 
4.8 Cholesteryl ester transfer protein inhibitors 
Cholesteryl ester transfer protein CETP is a hydrophobic glycoprotein promoting a net mass 
transfer of cholesteryl esters from the nonatherogenic HDL fraction to the potentially 
proatherogenic non-HDL, an event followed by a reciprocal transfer of TGs from LDL, VLDL to 
HDL (184). CETP inhibitors prevent neutral lipid transfers between HDLs and TG-rich 
lipoproteins, including VLDL, markedly raising HDL-C levels and, to a lesser extent,  lowering 
LDL-C, depending on their potency (185). Overall, CETP inhibitors that have reached late stage 
clinical development are categorized into CETP inhibitors (torcetrapib, evacetrapib and 
anacetrapib) and modulators (dalcetrapib) (14). Despite the beneficial influence on cholesterol 
metabolism, off-target effects and lack of reduction in CV events and mortality (with 
torcetrapib, dalcetrapib and evacetrapib) have highlighted the complex, unclear beneficial 
mechanism of CETP inhibition (186).  
In the ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in 
Atherosclerotic Events) trial, recruiting 15,067 patients at high CV risk, administration of 
torcetrapib (60 mg) on an atorvastatin background (10, 20, 40 and 80 mg), raised HDL-C by 
+70.3% with a – 27.9% reduction in LDL-C; no changes in hsCRP were found (+0.04 mg/L). The 
trial was stopped after a 18-month follow-up after the observation of increased mortality and 
morbidity risk (187) (Table 1). A similar trend in lipoprotein changes was reported in the 
ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with 
Evacetrapib in Patients at a High Risk for Vascular Outcomes) trial with evacetrapib. Among the 
12,092 high-risk vascular patients, randomly assigned to receive evacetrapib (130 mg), HDL-C 
was impressively increased by +131.6% with a -37.1% drop in LDL-C. Levels of hsCRP were 
significantly higher (+8.6%) in the evacetrapib vs the placebo group. The trial was stopped for 
futility after a median follow-up of 26 months (188) (Table 1). 
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 The only trial, i.e. the REVEAL (Randomized EValuation of the Effects of Anacetrapib 
Through Lipid-modification) study, demonstrating a significant 9% proportional reduction of 
major coronary events upon anacetrapib administration (100 mg), reported no data on hsCRP. 
In this study, a + 104% rise of HDL-C and a -41% reduction of LDL-C (as quantified by a direct 
method) were found (189). Interestingly, with a weaker CETP inhibitor, i.e. dalcetrapib in the 
dal-OUTCOMES trial – the HDL-C rise was +30%, with no change in LDL-C and a +18% increment 
of hsCRP (190) (Table 1). Re-evaluation of all of these apparently negative results by using a 
pharmacogenomic approach has very recently unearthed unexpected findings. Among carriers 
of the AA genotype of the ADCY9 (adenylate cyclase type 9) gene, administration of dalcetrapib 
significantly reduced by 39% the risk of CV events with no elevation in hsCRP (191). This 
observation is now the object of the on-going dal-GenE trial (Effect of Dalcetrapib vs Placebo on 
CV Risk in a Genetically Defined Population With a Recent ACS; NCT02525939) (Table 1). 
CETP antagonism does not appear to be related to clear-cut anti-inflammatory changes. 
Indeed, all studied antagonists had a tendency to induce hsCRP rises (Figure 1). 
 
4.9 Nicotinic acid 
Nicotinic acid (niacin or vitamin B3) is a natural compound exerting a variety of activities on 
lipids, both cholesterol and TGs, at pharmacological doses, i.e. about 1-2 g/day (192). Nicotinic 
acid (NA) exerts a powerful antilipolytic activity, resulting in reduced free fatty acid (FFA) 
release from the adipose tissue to the liver where FFAs may be resynthesized to TGs (193). 
Some Authors believe that NA may exert, similar to fibrates, an activity as a fraudulent fatty 
acid, i.e. exerting a moderate stimulation on peroxisomal proliferation as a PPARα agonist 
(194). In this way NA may activate lipoprotein lipase and, as a consequence, reduce TGs, to a 
lesser extent LDL-C, and raise HDL-C levels (195). An analog of niacin, i.e. acipimox, has a more 
prolonged antilipolytic activity (196) and by this mechanism appears to be particularly effective 
in patients with the metabolic syndrome (197). 
The profile of NA, particularly the significant positive impact on HDL-C levels, has led to 
large placebo controlled clinical studies in patients with atherosclerotic vascular disease, i.e. the 
Atherothrombotic Intervention in MetS with Low HDL/high triglycerides: Impact on Global 
Health Outcomes (AIM-HIGH) (198) and Heart Protection Study 2-Treatment of HDL to Reduce 
the Incidence of Vascular Events (HPS2-THRIVE) (199) both with extended release (ER) NA. 
These studies evaluated ER NA in combination with the anti-flushing agent laropiprant in 
patients on intensive statin therapy, plus ezetimibe when required to reach predetermined 
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 LDL-C target levels. Neither of these studies resulted in a significant reduction of major 
coronary disease. It is possible that this negative finding reflects the low baseline levels of LDL-C 
(<75 mg/dl) with associated modest reductions of LDL-C levels, although both studies reported 
a significant increase of HDL-C (200).  
ER NA treatment is typically associated within the induction of insulin resistance (201). A 
likely mechanism is that the antilipolytic of NA is transient, followed by daily rises of FFA levels 
(195). The opposite case is that of acipimox, with a stable reduced lipolysis, also resulting in an 
improved lipid profile, increased affinity of LDL for their receptors (202) and reduced insulin 
resistance (197).  
A very recent evaluation of ER NA given for 8 weeks in patients with dyslipidemia and 
metabolic syndrome (203), with 300 mg/day aspirin to reduce flushing, reported increased 
insulin resistance: the HOMA index rose, in fact, from 5.80 to 7.67 (+32%, p <0.015). This 
treatment also led to significant reductions of TG (-31%) LDL-C (-17%) and Lp(a) (-21%) with 
concomitant reductions of apo B, apo CIII and apo E. There were no changes in plasma apo AI 
but HDL-C levels rose by +13.2%. 
Inflammatory markers are typically reduced by NA treatment. The cell-surface receptor 
GPR109A also known as hydroxycarboxylic acid receptor 2 (HCA2 or HCAR2) or niacin receptor 
1 (NIACR1), is activated by NA. GPR109A is a G-protein-coupled receptor expressed in adipose 
tissue and immune cells (204). GPR109A KO mice show enhanced susceptibility to experimental 
inflammatory conditions (205). Extensive animal studies have confirmed the significant anti-
inflammatory potential of NA exerted via by the GPR109A receptor (206). In the above 
reported study in MetS patients (203), NA reduced hsCRP by 40% (from 2.7+0.55 to 1.7+0.25 
mg/L) (Table 1), and similar, albeit lesser reductions, were noted for of TNF-α, PAI1 (probably 
reflecting the  reduction of TGs)  and IL-7, not IL-6. It appears that the NA mediated reduction 
of CIII appeared to be tightly linked to an entire inflammatory cluster through hsCRP. 
The findings of numerous studies of NA and analogs have not provided consistent 
results. In a comparative evaluation of NA and fenofibrate, the former was more effective at 
lowering hsCRP but fenofibrate led to more a beneficial lipoprotein profile (207). Acipimox may 
possibly have a different profile: this drug reduces neutrophil migration, with no effect on 
monocytes (197).  
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 5. Conclusions 
Analysis of results from the more recent clinical trials conducted with the PCSK9 inhibitor 
evolocumab (FOURIER) and with the IL-1 antagonist canakinumab (CANTOS) confirmed the 
pioneer hypothesis by Ridker et al, i.e. that the largest CV event reduction can be obtained 
when treating patients with both LDL-C > 70 mg/dl and hsCRP >2 mg/L (3). Overall, the 
observation that canakinumab has no effects on diabetes and LDL cholesterolemia indicates 
that benefits on major CV events are due to inhibition of inflammation (57). However, it should 
be reminded that of the two other RCTs addressing the issue of inflammation and CV risk, CIRT 
(Cardiovascular Inflammation Reduction Trial) has been ended in May 2018 after recruiting 
4,786 patients; the COLCOT (Colchicine Cardiovascular Outcomes Trial) is still ongoing. Results 
of CIRT are expected in November 2018. This study evaluated patients with prior MI and either 
type 2 diabetes or MetS, treated with low-dose methotrexate or placebo, primary endpoints 
being nonfatal MI, nonfatal stroke, and cardiovascular death (208). The COLCOT (Colchicine 
Cardiovascular Outcomes Trial) study instead aimed at evaluating whether long-term colchicine 
reduces rates of CV events in post-MI patients (209, 210). 
The new biological agents thus contribute to dichotomizing the pharmacological action 
of statins, evolocumab lowering only the LDL-C levels and canakinumab reducing only systemic 
inflammation. The results of the two most recent trials (FOURIER and CANTOS) add, however, 
an extra-layer of complexity on the relationship between lipids, inflammation and CVD risk. 
Indeed, in the FOURIER trial, baseline hsCRP and achieved LDL-C were both factors 
independently associated with major adverse CV events, reaffirming the concept of raised 
inflammatory markers (in particular hsCRP) and residual CV risk (143). 
Inflammation and cholesterolemia have thus different pathophysiological roles on 
atherosclerosis and CV risk (211). Lipid lowering agents with “pleiotropic” effects, i.e. statins, 
fibrates and, possibly, bempedoic acid, provide a potentially more effective approach to CV 
prevention. Looking back at 1997 when Maseri defined CRP as the “hidden side of the moon” 
(212), as a consequence of the never-ending debate relative to the direct causal role of 
inflammation in CVD, hsCRP appears to be of value in identifying high risk individuals, thus, 
guiding, in particular, lipid lowering therapy. Indeed, in the ASCOT (Anglo Scandinavian Cardiac 
Outcomes Trial) there was a 25% greater relative risk reduction among subjects with on-
treatment hsCRP < 1.83 mg/dL, a finding consistent across CARE, PROVE IT, REVERSAL, A to Z, 
and JUPITER trials (213). 
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 The most recent observations with the newer PCSK9 antagonist, alirocumab, require a 
more definite answer as to which patients will benefit the most from a profound LDL-C 
reduction. A recent meta-analysis evaluating threshold LDL-C levels for achieving CV risk 
reduction concluded, in fact, that patients with baseline LDL-C  100mg/dL receiving a more 
intensive treatment are those benefitting the most (9). Evaluations of MACEs in the ODYSSEY 
trial did not show a clear benefit in patients with LDL-C <100 mg/dL. In the future, the effects of 
PCSK9 antagonism by RNA interference (inclisiran) will provide further, more stable cholesterol 
reductions and indications on their possible links with vascular inflammation. These 
pharmacological aspects of lipid lowering treatments will need to be more extensively 
addressed, both because of the present uncertainty on, e.g., statin treatment in elderlies (214) 
and because of the exposure of many patients to a growing number of drugs. 
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 Tables and figures 
 
Figure 1. Pharmacological changes of LDL-C and CRP. Modified from Kinlay S et al. (6). 
CETP, Cholesteryl ester transfer protein; PCSK9, Proprotein convertase subtilisin/kexin 9;  
 
Figure 2. Hazard ratios for major CV events, cardiovascular mortality and all-cause mortality 
were stratified according to on-treatment hsCRP concentrations at 3 months. 
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  Clinical study hsCRP (mg/L) LDL-C (mg/dL) 
  Pre post Δ pre post Δ 
Monoclonal 
antibody anti IL-
1 
 
      
Canakinumab (52) CANTOS 4.3 2.0 -37% vs placebo 82.4 84.7 
+3.1% vs 
placebo 
        
Statins        
Pravastatin (215, 
216) 
CARE 2.3 1.9 
-17.4% vs 
baseline 
139.2 98.0 
-32% vs 
baseline 
Pravastatin (217) PRINCE 2.4 2.0 
-16.6% vs 
baseline 
142.9 97.5 
-31.8% vs 
baseline 
Lovastatin (2, 218) AFCAPS/TexCAPS 1.6 1.3 
-14.8% vs 
baseline 
156.0 115.0 
-27% vs 
baseline 
Atorvastatin (219, 
220) 
MIRACL 11.5 2.9 -75.0% vs placebo 135.0 72.0 -40% vs placebo 
Pravastatin (76) REVERSAL 3.0 2.9 -5.2% vs baseline 150.2 110.4 
-25.2% vs 
baseline 
Atorvastatin (76) REVERSAL 3.0 1.8 
-36.4% vs 
baseline 
150.2 78.9 
-46.3% vs 
baseline 
Pravastatin (73, 
221) 
PROVE IT–TIMI 
22 
11.9 2.1 
-82.4% vs 
baseline 
106.0 95.0 
-10.4% vs 
baseline 
Atorvastatin (73, 
221) 
PROVE IT–TIMI 
22 
12.2 1.3 
-89.3% vs 
baseline 
106.0 62.0 
-41.5% vs 
baseline 
Simvastatin (222) 
A-to-Z Trial 
2.01 0.17 
-91.5% vs 
baseline 
112.0 62.0 
-44.6% vs 
baseline 
Rosuvastatin (74) JUPITER 4.2 2.2 
-47.6% vs 
baseline 
108.0 55.0 
-49.1% vs 
baseline 
Simvastatin (223) 
Heart Protection 
Study 
3.07 2.24 -27% vs baseline 127.9 95.9 
-25% vs 
baseline 
Atorvastatin (224) ASCOT 2.4 1.8 
-25.8% vs 
baseline 
136.8 85.6 
-38.7% vs 
baseline 
Atorvastatin (225) CARDS 1.3 1.2 -9.8% vs baseline 121.0 60.0 
-50.4% vs 
baseline 
        
Ezetimibe        
Ezetimibe + 
atorvastatin (226) 
 
2.19 1.98 
-10% vs 
atorvastatin 
101.8 89.5 
-12.1% vs 
atorvastatin 
Ezetimibe + 
rosuvastatin (227) 
EXPLORER 1.7 1.2 
-17.8% vs 
rosuvastatin 
81.5 56.9 
-30.2% vs 
rosuvastatin 
Ezetimibe + 
Simvastatin (88) 
SHARP 1.1 0.99 -21% vs placebo 106.0 68.9 -35% vs placebo 
Ezetimibe + 
Simvastatin (87) 
IMPROVE-IT 1.9 1.6 
-14% vs 
simvastatin 
67.7 49.9 
-20% vs 
simvastatin 
        
Fibrates        
Fenofibrate (105) FIELD 1.8 2.5 +38.9 % vs 120 103 -14.2% vs  
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 baseline  baseline 
Fenofibrate + 
Simvastatin (108) 
DIACOR 2.2 2.1  
-15.9% vs 
baseline 
136.9 92.0 
-29.1 % vs 
baseline 
Fenofibrate + 
Ezetimibe (111) 
 
2.5 1.9 
-25.3% vs 
baseline 
159.7 124.6 
-22.0% vs 
baseline 
        
Monoclonal 
antibody anti 
PCSK9 
 
      
Evolocumab (143, 
228) 
FOURIER 1.7 1.4  0% vs placebo 92.0 30.0 -59% vs placebo 
Bococizumab (149) SPIRE-1 and -2 1.88 1.84 +6.6% vs placebo§ 96.5 34.7 
-60.5%vs 
placebo§ 
Alirocumab (140) 
ODYSSEY 
COMBOII 
3.58 3.51 -2% vs baseline 108.0 53.3 
-49.5% vs 
baseline 
        
Bile acid 
sequestrants 
       
Colesevelam HCl + 
statins (163) 
 2.0 1.3 -23.3% vs statins 132.6 111.3 -21% vs statins 
Colestimide (164)  10.16 5.86 -42.3% 151.2 127.3 
-14.4% vs 
baseline 
        
MTP inhibitor        
Lomitapide (168) 
 
NCT00943306 
2.0 1.1 
-45% vs  
baseline# 
356.0 189.0 
-45.5 % vs 
baseline# 
        
Bempedoic acid        
Bempedoic acid + 
ezetimibe (181) 
CLEAR Tranquility 2.2  
-31% vs  
placebo 
129.8  
-28.5% vs  
placebo  
        
CETP inhibitor        
Torcetrapib (187) ILLUMINATE 1.30 1.34 +1% vs placebo 79.7 60.5 -24% vs placebo 
Dalcetrapib (190, 
191) 
dal-OUTCOMES 1.5 1.6 +18% vs placebo  76.4 76.4 no changes 
dal-OUTCOMES 
(analyzed for 
carriers of ADCY9 
AA genotype) 
1.71 1.61 -1.0 % vs placebo 76.0 - - 
Evacetrapib (188) ACCELERATE 1.52 1.65 +8.6% vs baseline 81.6 54.7 
-37.1% vs 
placebo 
        
Nicotinic acid        
Niacin (203) NCT01216956 2.7 1.6 -40% vs baseline 125 103 
-17% vs 
baseline 
        
#Data available at week 126; § Data available at week 14; -, not available  
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